24-Jun-2022 – Strides Pharma Science rallied 7.70% to Rs 336.50 after the company’s subsidiary Biolexis and Akston Biosciences announce encouraging top-line results from phase II/III trial of their thermostable 2nd gen COVID-19 vaccine.

Total 1,600 healthy volunteers participated. Out of which, 100 participated in an open-label bridging study and 1,500 in Phase II/III, double-blind, placebo-controlled trial. The vaccine was well tolerated, with no reported safety issues and is shelf-stable for over six months at room temperature at 25 celsius and potency for one month at 37 celsius. The interim analysis showed 91% seroconversion rate at day 56.